Is the Diminished Incretin Effect in Type 2 Diabetes Just an Epi-Phenomenon of Impaired β-Cell Function?
Open accessThe DOI matches its Crossref record; 70 of the 72 references it cites were found in a registry or an index.
Abstract
Type 2 diabetes is characterized by a deficit in β-cell mass, impaired insulin secretion in response to various stimuli (1–3), as well as a variable extent of insulin resistance (4). More specifically, regarding β-cell function, a significant reduction of the incretin effect, i.e., the postprandial augmentation of insulin secretion by gut hormones, has been described in patients with type 2 diabetes (5). Thus, while the two incretin hormones gastric inhibitory polypeptide (glucose-dependent insulinotopic polypeptide [GIP]) and glucagon-like peptide 1 (GLP-1) are held responsible for ∼50–70% of the postprandial insulin responses in healthy individuals (6), their contribution to the overall insulin responses after oral glucose ingestion may amount to <20% in patients with type 2 diabetes (5,7). The reasons underlying the loss of incretin activity in type 2 diabetes are still incompletely understood. The present article reviews the available evidence regarding disturbances in the enteroinsular axis in patients with type 2 diabetes and provides possible explanations for their etiologies, focusing on the personal experience of the authors. ### Secretion of incretin hormones in patients with type 2 diabetes. Because the incretin effect has been related to the secretion and insulinotropic action of GIP and GLP-1 (8,9), it was obvious to compare these parameters between patients with type 2 diabetes and healthy control subjects: Regarding the secretion of GIP, elevated, normal, and reduced plasma levels have been described in patients with type 2 diabetes (10–15). However, taking together all the evidence available, the secretion of GIP appears to be relatively unchanged in type 2 diabetic patients. For GLP-1 release, the case is even more complex. Several studies have reported significant reductions in GLP-1 levels after mixed meal ingestion in patients with type 2 diabetes (10,16,17). In addition, one study has found minor impairments in GLP-1 levels in individuals with impaired glucose …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures







Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“The current consensus in the literature is that GLP-1 and GIP circulation levels are comparable between T2D patients and nondiabetic controls in response to nutrient challenges.158”
From A review of current trends with type 2 diabetes epidemiology, aetiology, pathogenesis, treatments and future perspectives (2021) · cites this paper as [158]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
β-Cell Deficit and Increased β-Cell Apoptosis in Humans With Type 2 Diabetes
Butler, A. E., Janson, J., Bonner-Weir, S., Ritzel, R., Rizza, R. A., & Butler, P. C. (2003) · Diabetes · doi:10.2337/diabetes.52.1.102 · Cited by 4,011
The Triumvirate: β-Cell, Muscle, Liver: A Collusion Responsible for NIDDM
DeFronzo, R. A. (1988) · Diabetes · doi:10.2337/diab.37.6.667 · Cited by 2,456
Nauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Self-citationReduced incretin effect in Type 2 (non-insulin dependent) diabetes
Nauck, M., Stöckmann, F., Ebert, R., & Creutzfeldt, W. (1986) · Diabetologia · doi:10.1007/bf02427280 · Cited by 1,307 · cited 3×
“The diminished incretin effect in patients with type 2 diabetes was described more than 20 years ago (5), but even now the underlying causes remain elusive.”
BackgroundSelf-citationNauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092 · cited 1×
“By these means, the hyperglycemia in patients with type 2 diabetes can readily be normalized by the intravenous administration of GLP-1 (26), even at relatively low doses (27).”
BackgroundSelf-citationVilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
NAUCK, M. A., HOMBERGER, E., SIEGEL, E. G., ALLEN, R. C., EATON, R. P., EBERT, R., & CREUTZFELDT, W. (1986) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem-63-2-492 · Cited by 874
Self-citationDeterminants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients
Toft-Nielsen, M.-B., Damholt, M. B., Madsbad, S., Hilsted, L. M., Hughes, T. E., Michelsen, B. K., & Holst, J. J. (2001) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.86.8.7750 · Cited by 869
Scrocchi, L. A., Brown, T. J., Maclusky, N., Brubaker, P. L., Auerbach, A. B., Joyner, A. L., & Drucker, D. J. (1996) · Nature Medicine · doi:10.1038/nm1196-1254 · Cited by 793
Creutzfeldt, W. (1979) · Diabetologia · doi:10.1007/bf01225454 · Cited by 731
Research works printed but not linked: 5
- Meier, 2005, Insulin secretion, 961
- Ebert, 1980, Hypo- and hypersecretion of GIP in maturity-onset diabetics (Abstract), Diabetologia, 19, 271
- Nauck, 2004, Gastric inhibitory polypeptide and glucagon-like peptide-1 in the pathogenesis of type 2 diabetes, Diabetes, 53, S190, 10.2337/diabetes.53.suppl_3.S190 · DOI · Paper page
- Knop, 2007, Reduced incretin effect in type 2 diabetes: cause or consequence of the diabetic state?, Diabetes, 56, 1951, 10.2337/db07-0100 · DOI · Paper page
- Pfeifer, 1981, Insulin secretion in diabetes mellitus, Am J Med, 70, 579, 10.1016/0002-9343(81)90579-9 · DOI · Paper page
Cited by
Incretin hormones: Their role in health and disease
Nauck, M. A., & Meier, J. J. (2018) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13129 · Cited by 950
Self-citationType 2 diabetes across generations: from pathophysiology to prevention and management
Nolan, C. J., Damm, P., & Prentki, M. (2011) · The Lancet · doi:10.1016/s0140-6736(11)60614-4 · Cited by 923
Steinert, R. E., Feinle-Bisset, C., Asarian, L., Horowitz, M., Beglinger, C., & Geary, N. (2017) · Physiological Reviews · doi:10.1152/physrev.00031.2014 · Cited by 578
Nauck, M. A., & Meier, J. J. (2016) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(15)00482-9 · Cited by 503
Self-citationReed, J., Bain, S., & Kanamarlapudi, V. (2021) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s319895 · Cited by 441
Nauck, M. A., & D‘Alessio, D. A. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01604-7 · Cited by 407
Self-citationNauck, M. A., Quast, D. R., Wefers, J., & Pfeiffer, A. F. H. (2021) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.14496 · Cited by 388
Self-citationDynamics of insulin secretion and the clinical implications for obesity and diabetes
Seino, S., Shibasaki, T., & Minami, K. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45680 · Cited by 364
de la Monte, S. M. (2017) · Drugs · doi:10.1007/s40265-016-0674-0 · Cited by 331
Nauck, M. A. (2011) · The American Journal of Medicine · doi:10.1016/j.amjmed.2010.11.002 · Cited by 295
Self-citationLoss of Incretin Effect Is a Specific, Important, and Early Characteristic of Type 2 Diabetes
Holst, J. J., Knop, F. K., Vilsbøll, T., Krarup, T., & Madsbad, S. (2011) · Diabetes Care · doi:10.2337/dc11-s227 · Cited by 280
Mechanisms of action and therapeutic applications of GLP-1 and dual GIP/GLP-1 receptor agonists
Liu, Q. K. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1431292 · Cited by 265
“On the other hand, fasting plasma levels of bioactive GLP-1 typically fall within the ranges of 5 - 15 pM (33, 37, 38) and could increase 3 – 5 fold postprandially.”
BackgroundCeriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Esposito, K., Giugliano, D., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc12-2469 · Cited by 204
Diabetes and beta cell function: from mechanisms to evaluation and clinical implications
Cernea, S., & Dobreanu, M. (2013) · Biochemia Medica · doi:10.11613/bm.2013.033 · Cited by 203
Yabe, D., & Seino, Y. (2011) · Progress in Biophysics and Molecular Biology · doi:10.1016/j.pbiomolbio.2011.07.010 · Cited by 188
Glucagon-Like Peptide-1: Glucose Homeostasis and Beyond
Cho, Y. M., Fujita, Y., & Kieffer, T. J. (2014) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021113-170315 · Cited by 174
Approach to the patient with mody-monogenic diabetes
Broome, D. T., Pantalone, K. M., Kashyap, S. R., & Philipson, L. H. (2021) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaa710 · Cited by 159
Real-time trafficking and signaling of the glucagon-like peptide-1 receptor
Roed, S. N., Wismann, P., Underwood, C. R., Kulahin, N., Iversen, H., Cappelen, K. A., Schäffer, L., Lehtonen, J., Hecksher-Soerensen, J., Secher, A., et al. (2014) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.11.010 · Cited by 153
Targeting the glucagon receptor family for diabetes and obesity therapy
Cho, Y. M., Merchant, C. E., & Kieffer, T. J. (2012) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2012.05.009 · Cited by 156
Østoft, S. H., Bagger, J. I., Hansen, T., Pedersen, O., Faber, J., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Diabetes Care · doi:10.2337/dc13-3007 · Cited by 136
Ceriello, A., Esposito, K., Testa, R., Bonfigli, A. R., Marra, M., & Giugliano, D. (2011) · Diabetes Care · doi:10.2337/dc10-1949 · Cited by 134
Lorenz, M., Evers, A., & Wagner, M. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.05.022 · Cited by 127
Nakatani, Y., Maeda, M., Matsumura, M., Shimizu, R., Banba, N., Aso, Y., Yasu, T., & Harasawa, H. (2017) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.05.009 · Cited by 126
DPP-4 inhibitors in the treatment of type 2 diabetes
Duez, H., Cariou, B., & Staels, B. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.11.028 · Cited by 110
Postprandial hyperglycemia and postprandial hypertriglyceridemia in type 2 diabetes
Hiyoshi, T., Fujiwara, M., & Zemin, Y. (2018) · Journal of Biomedical Research · doi:10.7555/jbr.31.20160164 · Cited by 126
Shah, P., Ardestani, A. D., Dharmadhikari, G., Laue, S., Schumann, D., Kerr-Conte, J. A., Pattou, F. N., Klein, T., & Maedler, K. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-1029 · Cited by 108
The role of glucagon on type 2 diabetes at a glance
Godoy-Matos, A. F. (2014) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-6-91 · Cited by 99
Christensen, M. B., Calanna, S., Holst, J. J., Vilsbøll, T., & Knop, F. K. (2014) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2013-3644 · Cited by 99
Aulinger, B. A., Bedorf, A., Kutscherauer, G., de Heer, J., Holst, J. J., Göke, B., & Schirra, J. R. J. (2013) · Diabetes · doi:10.2337/db13-1455 · Cited by 98
Lixisenatide for type 2 diabetes mellitus
Christensen, M., Knop, F. K., Vilsbøll, T., & Holst, J. J. (2011) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2011.562191 · Cited by 84
Incretin physiology and pathophysiology from an A sian perspective
Cho, Y. M. (2014) · Journal of Diabetes Investigation · doi:10.1111/jdi.12305 · Cited by 80
Wice, B. M., Reeds, D. N., Tran, H. D., Crimmins, D. L., Patterson, B. W., Dunai, J., Wallendorf, M. J., Ladenson, J. H., Villareal, D. T., & Polonsky, K. S. (2012) · Diabetes · doi:10.2337/db11-1451 · Cited by 74
Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
Polyphenols: Potential Future Arsenals in the Treatment of Diabetes
Solayman, M., Ali, Y., Alam, F., Islam, M. A., Alam, N., Khalil, M. I., & Gan, S. H. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666151125001111 · Cited by 86
Thondam, S. K., Daousi, C., Wilding, J. P. H., Holst, J. J., Ameen, G. I., Yang, C., Whitmore, C., Mora, S., & Cuthbertson, D. J. (2017) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00347.2016 · Cited by 71
Type-3c Diabetes Mellitus, Diabetes of Exocrine Pancreas - An Update
Bhattamisra, S. K., Siang, T. C., Rong, C. Y., Annan, N. C., Sean, E. H. Y., Xi, L. W., Lyn, O. S., Liew, H. S., Choudhury, H., Pandey, M., et al. (2019) · Current Diabetes Reviews · doi:10.2174/1573399815666190115145702 · Cited by 81
Jensen, D. H., Aaboe, K., Henriksen, J. E., Vølund, A., Holst, J. J., Madsbad, S., & Krarup, T. (2012) · Diabetologia · doi:10.1007/s00125-012-2459-7 · Cited by 76
Wewer Albrechtsen, N. J., Hornburg, D., Albrechtsen, R., Svendsen, B., Toräng, S., Jepsen, S. L., Kuhre, R. E., Hansen, M., Janus, C., Floyd, A., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.03.034 · Cited by 69
Diabetes: Mechanism, Pathophysiology and Management-A Review
Siddiqui, A. A., Siddiqui, S. A., Ahmad, S., Siddiqui, S., Ahsan, I., & Sahu, K. (2013) · International Journal of Drug Development and Research · Cited by 110
Insulin resistance: a connecting link between Alzheimer's disease and metabolic disorder
Kshirsagar, V., Thingore, C., & Juvekar, A. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-020-00622-2 · Cited by 66
The nutritional management of type 3c (pancreatogenic) diabetes in chronic pancreatitis
Duggan, S. N., Ewald, N., Kelleher, L., Griffin, O. M., Gibney, J., & Conlon, K. C. (2016) · European Journal of Clinical Nutrition · doi:10.1038/ejcn.2016.127 · Cited by 68
Berglund, L. M., Lyssenko, V., Ladenvall, C., Kotova, O., Edsfeldt, A., Pilgaard, K., Alkayyali, S., Brøns, C., Forsblom, C., Jonsson, A., et al. (2016) · Diabetes · doi:10.2337/db15-0122 · Cited by 65
Ceriello, A., Novials, A., Ortega, E., Canivell, S., La Sala, L., Pujadas, G., Bucciarelli, L., Rondinelli, M., & Genovese, S. (2013) · Diabetes Care · doi:10.2337/dc13-0750 · Cited by 65
Incretin dysfunction in type 2 diabetes: Clinical impact and future perspectives
Ahrén, B. (2013) · Diabetes & Metabolism · doi:10.1016/j.diabet.2013.03.001 · Cited by 64
Clinical pharmacology of glucagon-like peptide-1 receptor agonists
Sfairopoulos, D. G., Liatis, S., Tigas, S. K., & Liberopoulos, E. N. (2018) · HORMONES · doi:10.1007/s42000-018-0038-0 · Cited by 73
In Vitro and In Vivo Antidiabetic Potential of Monoterpenoids: An Update
Kury, L. T. A., Abdoh, A., Ikbariah, K., Sadek, B. S., & Mahgoub, M. (2021) · Molecules · doi:10.3390/molecules27010182 · Cited by 78
Vardarli, I., Nauck, M. A., Köthe, L. D., Deacon, C. F., Holst, J. J., Schweizer, A., & Foley, J. E. (2011) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2010-2178 · Cited by 61
Self-citationBeta cell connectivity in pancreatic islets: a type 2 diabetes target?
Rutter, G. A., & Hodson, D. J. (2014) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-014-1755-4 · Cited by 67
de la Monte, S. M. (2019) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-13-3540-2_4 · Cited by 58
Vergès, B., Bonnard, C., & Renard, E. (2011) · Diabetes & Metabolism · doi:10.1016/j.diabet.2011.07.001 · Cited by 58
Herzberg‐Schäfer, S., Heni, M., Stefan, N., Häring, H. ‐., & Fritsche, A. (2012) · Diabetes, Obesity and Metabolism · doi:10.1111/j.1463-1326.2012.01648.x · Cited by 57
The role of beta cell heterogeneity in islet function and insulin release
Nasteska, D., & Hodson, D. J. (2018) · Journal of Molecular Endocrinology · doi:10.1530/jme-18-0011 · Cited by 65
McCormack, P. L. (2014) · Drugs · doi:10.1007/s40265-013-0172-6 · Cited by 65
Gabe, M. B. N., van der Velden, W. J. C., Gadgaard, S., Smit, F. X., Hartmann, B., Bräuner‐Osborne, H., & Rosenkilde, M. M. (2020) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.13289 · Cited by 55
Kang, Z. F., Deng, Y., Zhou, Y., Fan, R. R., Chan, J. C. N., Laybutt, D. R., Luzuriaga, J., & Xu, G. (2013) · Diabetologia · doi:10.1007/s00125-012-2776-x · Cited by 54
Østoft, S. H., Bagger, J. I., Hansen, T., Pedersen, O., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2014) · Diabetes · doi:10.2337/db13-1878 · Cited by 55
Albiglutide: First Global Approval
Poole, R. M., & Nowlan, M. L. (2014) · Drugs · doi:10.1007/s40265-014-0228-2 · Cited by 49
Milk in the prevention and management of type 2 diabetes: The potential role of milk proteins
Hidayat, K., Du, X., & Shi, B. (2019) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.3187 · Cited by 54
Belinova, L., Kahleova, H., Malinska, H., Topolcan, O., Vrzalova, J., Oliyarnyk, O., Kazdova, L., Hill, M., & Pelikanova, T. (2014) · PLoS ONE · doi:10.1371/journal.pone.0107561 · Cited by 48
Hansen, K. B., Vilsbøll, T., Bagger, J. I., Holst, J. J., & Knop, F. K. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-2594 · Cited by 56
Genetic variants affecting incretin sensitivity and incretin secretion
Müssig, K., Staiger, H., Machicao, F. E., Häring, H., & Fritsche, A. (2010) · Diabetologia · doi:10.1007/s00125-010-1876-8 · Cited by 49
An overview of new GLP-1 receptor agonists for type 2 diabetes
Tomlinson, B., Hu, M., Zhang, Y., Chan, P., & Liu, Z.-M. (2016) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2016.1123249 · Cited by 44
Kohl, B., Hammond, M. S., Cucchiara, A. J., & Ochroch, E. A. (2013) · Journal of Cardiothoracic and Vascular Anesthesia · doi:10.1053/j.jvca.2013.06.021 · Cited by 46
Clinical potential of lixisenatide once daily treatment for type 2 diabetes mellitus
Petersen, B., & Christensen (2013) · Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy · doi:10.2147/dmso.s45379 · Cited by 42
Diabetic Gastroparesis and Its Impact on Glycemia
Chang, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.08.007 · Cited by 45
Diabetic gastroparesis—Backwards and forwards
Chang, J., Rayner, C. K., Jones, K. L., & Horowitz, M. (2011) · Journal of Gastroenterology and Hepatology · doi:10.1111/j.1440-1746.2010.06573.x · Cited by 40
Mari, A., Bagger, J. I., Ferrannini, E., Holst, J. J., Knop, F. K., & Vilsbøll, T. (2013) · PLoS ONE · doi:10.1371/journal.pone.0073154 · Cited by 40
The incretin effect in Korean subjects with normal glucose tolerance or type 2 diabetes
Oh, T. J., Kim, M. Y., Shin, J. Y., Lee, J. C., Kim, S., Park, K. S., & Cho, Y. M. (2014) · Clinical Endocrinology · doi:10.1111/cen.12167 · Cited by 40
Holst, J. J., & McGill, M. A. (2011) · Clinical Drug Investigation · doi:10.2165/11595370-000000000-00000 · Cited by 44
Belinova, L., Kahleová, H., Malínská, H., Topolčan, O., Windrichová, J., Oliyarnyk, O., Kazdová, L., Hill, M., & Pelikánová, T. (2017) · PLoS ONE · doi:10.1371/journal.pone.0174820 · Cited by 44
Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity
Opinto, G., Natalicchio, A., & Marchetti, P. (2013) · Archives of Physiology and Biochemistry · doi:10.3109/13813455.2013.812664 · Cited by 51
Kimura, T., Obata, A., Shimoda, M., Hirukawa, H., Kanda‐Kimura, Y., Nogami, Y., Kohara, K., Nakanishi, S., Mune, T., Kaku, K., et al. (2018) · Diabetes & Metabolism · doi:10.1016/j.diabet.2017.10.007 · Cited by 37
Pharmacological management of type 2 diabetes: the potential of incretin‐based therapies
Charbonnel, B. H., & Cariou, B. (2010) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2010.01317.x · Cited by 42
Eriksen, M., Jensen, D. H., Tribler, S., Holst, J. J., Madsbad, S., & Krarup, T. (2015) · Diabetologia · doi:10.1007/s00125-015-3522-y · Cited by 36
GIP’s involvement in the pathophysiology of type 2 diabetes
Christensen, M. B., Gasbjerg, L. S., Heimbürger, S. M., Stensen, S., Vilsbøll, T., & Knop, F. K. (2020) · Peptides · doi:10.1016/j.peptides.2019.170178 · Cited by 35
Manipulation of Post-Prandial Hyperglycaemia in Type 2 Diabetes: An Update for Practitioners
Shibib, L., Al-Qaisi, M., Guess, N. D., Miras, A. D., Greenwald, S. E., Pelling, M., & Ahmed, A. (2024) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s458894 · Cited by 48
The pro-healing effect of exendin-4 on wounds produced by abrasion in normoglycemic mice
Bacci, S., Laurino, A., Manni, M. E., Landucci, E., Musilli, C., Siena, G. D., Mocali, A., & Raimondi, L. (2015) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2015.06.056 · Cited by 34
Jonik, S., Marchel, M., Grabowski, M., Opolski, G., & Mazurek, T. (2022) · Biology · doi:10.3390/biology11020288 · Cited by 33
Type 2 Diabetes Mellitus and Glucagon Like Peptide-1 Receptor Signalling
Thompson, K. A. (2013) · Clinical and Experimental Pharmacology · doi:10.4172/2161-1459.1000138 · Cited by 49
Mechanism of glucagon-like peptide 1 improvements in type 2 diabetes mellitus and obesity.
Nolen-Doerr, E., Stockman, M.-C., & Rizo, I. (2019) · Current Obesity Reports · doi:10.1007/s13679-019-00350-4 · Cited by 32
Incretins as a novel therapeutic strategy in patients with diabetes and heart failure
Khan, M. A., Deaton, C., Rutter, M. K., Neyses, L., & Mamas, M. A. (2012) · Heart Failure Reviews · doi:10.1007/s10741-012-9318-y · Cited by 36
Aroda, V. R., Capehorn, M. S., Chaykin, L., Frias, J. P., Lausvig, N. L., Macura, S., Lüdemann, J., Madsbad, S., Rosenstock, J., Tabak, O., et al. (2020) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13896 · Cited by 31
Renner, S., Blutke, A., Streckel, E., Wanke, R., & Wolf, E. (2015) · The Journal of Pathology · doi:10.1002/path.4655 · Cited by 35
Clinical Pharmacokinetics and Pharmacodynamics of Albiglutide
Brønden, A., Knop, F. K., & Christensen, M. (2017) · Clinical Pharmacokinetics · doi:10.1007/s40262-016-0499-8 · Cited by 33
Renal protection with glucagon-like peptide-1 receptor agonists
Vitale, M., Haxhi, J., Cirrito, T., & Pugliese, G. (2020) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2020.08.018 · Cited by 31
The incretin effect in critically ill patients: a case–control study
Nielsen, S. T., Janum, S., Krogh‐Madsen, R., Solomon, T. P. J., & Møller, K. (2015) · Critical Care · doi:10.1186/s13054-015-1118-z · Cited by 31
The Role of Incretin Therapy at Different Stages of Diabetes
Cernea, S. (2011) · The Review of Diabetic Studies · doi:10.1900/rds.2011.8.323 · Cited by 35
Vora, J. P., Bain, S. C., Damcı, T., Dzida, G. J., Hollander, P. A., Meneghini, L., & Ross, S. (2012) · Diabetes & Metabolism · doi:10.1016/j.diabet.2012.08.002 · Cited by 31
An Update in Incretin-Based Therapy: A Focus on Glucagon-Like Peptide-1 Receptor Agonists
Edwards, K. L., Stapleton, M., Weis, J., & Irons, B. K. (2012) · Diabetes Technology & Therapeutics · doi:10.1089/dia.2012.0098.edw · Cited by 32
Burugula, L., Mullangi, R., Pilli, N. R., Makula, A., Lodagala, D. S., & Kandhagatla, R. (2012) · Biomedical Chromatography · doi:10.1002/bmc.2751 · Cited by 28
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
Calanna, S., Urbano, F., Piro, S., Zagami, R. M., Pino, A. D., Spadaro, L., Purrello, F., & Rabuazzo, A. M. (2012) · European Journal of Endocrinology · doi:10.1530/eje-11-0765 · Cited by 29
Wagner, R. J., Staiger, H., Ullrich, S., Stefan, N., Fritsche, A., & Häring, H. (2014) · Molecular Metabolism · doi:10.1016/j.molmet.2014.01.001 · Cited by 27
Mikada, A., Narita, T., Yokoyama, H., Yamashita, R., Horikawa, Y., Tsukiyama, K., & Yamada, Y. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.09.040 · Cited by 27
Effects on pancreatic Beta and other Islet cells of the glucose-dependent insulinotropic polypeptide
Khan, R., Tomas, A., & Rutter, G. A. (2020) · Peptides · doi:10.1016/j.peptides.2019.170201 · Cited by 24
Gut Hormone Responses to Mixed Meal Test in New-Onset Prediabetes/Diabetes After Acute Pancreatitis
Pendharkar, S. A., Singh, R. G., Cervantes, A., DeSouza, S. V., Bharmal, S. H., & Petrov, M. S. (2018) · Hormone and Metabolic Research · doi:10.1055/a-0802-9569 · Cited by 24
Doğruel, H., & Balcı, M. K. (2019) · World Journal of Diabetes · doi:10.4239/wjd.v10.i8.446 · Cited by 28
Liu, Q., Garg, P., Hasdemir, B., Wang, L., Tuscano, E., Sever, E. N., Rivera, E. K., Hernandez, A. G. L., Yuan, T. Z., Kwan, E., et al. (2021) · mAbs · doi:10.1080/19420862.2021.1893425 · Cited by 24
Chowdhury, S., Wang, S., Patterson, B. W., Reeds, D. N., & Wice, B. M. (2013) · Regulatory Peptides · doi:10.1016/j.regpep.2013.10.003 · Cited by 24
Rabbani, N., & Thornalley, P. J. (2024) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2024.111905 · Cited by 25
Metadata
- Authors
- Meier, J. J., & Nauck, M. A.
- Affiliations
- St. Josef-Hospital (DE)
- Diabeteszentrum Bad Lauterberg (DE)
- Corresponding author
- Meier, Juris J.
- Venue
- Diabetes
- Publisher
- American Diabetes Association
- Published
- 2010-05-01
- Volume
- 59
- Issue
- 5
- Pages
- 1117-1125
- ISSN
- 0012-1797 (ISSN-L)
- 1939-327X
- PMC
- PMC2857890
- OpenAlex
- W2097621088
- Cited by
- 215
- References
- 72
- Citations by year
- 2026: 4 · 2025: 5 · 2024: 14 · 2023: 6 · 2022: 7 · 2021: 11 · 2020: 5 · 2019: 15 · 2018: 8 · 2017: 16 · 2016: 16 · 2015: 17 · 2014: 16 · 2013: 27 · 2012: 19
- FWCI
- 3.41
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Diabetes (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion, cc-by-nc-nd)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- type 2 diabetes, incretin effect, enteroinsular axis, glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, incretin secretion, postprandial insulin secretion, beta-cell mass, insulin resistance
- MeSH terms
- Diabetes Mellitus, Type 2, Gastric Inhibitory Polypeptide, Humans, Models, Biological, Insulin-Secreting Cells, Glucagon-Like Peptide 1, Incretins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.